Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
Bausch Health Companies Inc. amended term loan of $2,802,125,000 with JPMorgan Chase Bank, N.A. at (i) 3.75% per annum for Replacement Term Loans with an interest rate determined maturing January 15, 2031.
- Instrument
- term loan
- Principal
- $2,802,125,000
- Counterparty
- JPMorgan Chase Bank, N.A.
- Rate
- (i) 3.75% per annum for Replacement Term Loans with an interest rate determined
- Maturity
- January 15, 2031
- Event
- amendment
Exact text from the filing
The Fourth Amendment provides for a new $2,802,125,000 tranche of term loans maturing in 2031 (the "Replacement Term Loans"), the proceeds of which were used to refinance all of Bausch + Lomb’s outstanding term B loans due 2031 (the "Third Amendment Term Loans") and term B loans due 2028 (the "First Incremental Term Loans").
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
Bausch Health Companies Inc. amended Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, collateral agent, swingline lender and an issuing bank (effective 2026-01-02).
- Action
- amendment
- Agreement
- credit facility
- Counterparty
- JPMorgan Chase Bank, N.A., as administrative agent, collateral agent, swingline lender and an issuing bank
- Effective
- 2026-01-02
Exact text from the filing
On January 2, 2026, Bausch + Lomb Corporation (“Bausch + Lomb”), a subsidiary of Bausch Health Companies Inc., entered into an amendment (the “Fourth Amendment”) to the Credit and Guaranty Agreement, dated as of May 10, 2022
View on SEC.gov